Halozyme
HALO
119 hedge funds and large institutions have $1.2B invested in Halozyme in 2013 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 41 reducing their positions, and 11 closing their positions.
125% more call options, than puts
Call options by funds: $23M | Put options by funds: $10.3M
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
39% more capital invested
Capital invested by funds: $861M → $1.2B (+$336M)
8% more funds holding
Funds holding: 110 → 119 (+9)
2% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$27M |
| 2 |
First Eagle Investment Management
New York
|
+$16.7M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$4.05M |
| 4 |
Renaissance Technologies
New York
|
+$3.86M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$3.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$14.6M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$10.2M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$9.27M |
| 4 |
SLF
Sun Life Financial
Toronto,
Ontario, Canada
|
-$6.64M |
| 5 |
QF
QVT Financial
New York
|
-$3.87M |
HALO Hedge Fund Activity: Q4 2013 in Review
119 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q4 2013, worth a combined $1.2B — up 39% from $861M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new HALO positions and 11 closed out — a net gain of 10 holders — while 40 added to existing stakes and 41 trimmed.
The largest buyer was Iridian Asset Management, adding an estimated $27M. The largest seller was State Street, cutting an estimated $14.6M.
- 119 institutional investors held Halozyme (HALO) as of Q4 2013, up from 110 in Q3 2013.
- Funds reported $1.2B of Halozyme stock for Q4 2013, up 39% quarter-over-quarter.
- 21 funds opened new Halozyme positions in Q4 2013 and 11 closed out, a net change of +10 holders.
- The largest Halozyme buyer in Q4 2013 was Iridian Asset Management, an estimated $27M added.
- The largest Halozyme seller in Q4 2013 was State Street, an estimated $14.6M sold.
Based on aggregated 13F filings for Q4 2013.